期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 149, 期 2, 页码 250-257出版社
WILEY
DOI: 10.1111/j.1365-2141.2010.08083.x
关键词
diagnosis; essential thrombocythaemia; primary myelofibrosis; MPL exon 10; high resolution melt
类别
资金
- Leukaemia Research Fund
- Leukaemia and Lymphoma Society of America and Cancer Research UK
- Cancer Research UK [8961] Funding Source: researchfish
- Medical Research Council [G0800784B, G0800784] Funding Source: researchfish
- MRC [G0800784] Funding Source: UKRI
P>Approximately 50% of essential thrombocythaemia and primary myelo-fibrosis patients do not have a JAK2 V617F mutation. Up to 5% of these are reported to have a MPL exon 10 mutation but testing for MPL is not routine as there are multiple mutation types. The ability to routinely assess both JAK2 and MPL mutations would be beneficial in the differential diagnosis of unexplained thrombocytosis or myelofibrosis. We developed and applied a high resolution melt (HRM) assay, capable of detecting all known MPL mutations in a single analysis, for the detection of MPL exon 10 mutations. We assessed 175 ET and PMF patients, including 67 that were JAK2 V617F-negative by real time polymerase chain reaction (PCR). Overall, 19/175 (11%) patients had a MPL exon 10 mutation, of whom 16 were JAK2 V617F-negative (16/67; 24%). MPL mutation types were W515L (11), W515K (4), W515R (2) and W515A (1). One patient had both W515L and S505N MPL mutations and these were present in the same haemopoietic colonies. Real time PCR for JAK2 V617F analysis and HRM for MPL exon 10 status identified one or more clonal marker in 71% of patients. This combined genetic approach increases the sensitivity of meeting the World Health Organization diagnostic criteria for these myeloproliferative neoplasms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据